ACHL

Investor Moves

Investor	Portfolio Value	Portfolio Change	Position Change	Avg Buy Price	Current Price
Jim SimonsRenaissance Technologies $-623.8K ExitQ1 2025 $624k -- --
Ken GriffinCitadel Advisors $-18.0K ExitQ1 2025 $18k -- --
Jim SimonsRenaissance Technologies $-27.1K TrimQ4 2024 $27k -- --
Jim SimonsRenaissance Technologies $94.5K AddQ3 2024 $94k -- --
Ken GriffinCitadel Advisors $-50.0K ExitQ3 2024 $50k -- --
Jim SimonsRenaissance Technologies $555.2K AddQ2 2024 $555k -- --

Trade ACHL

About Achilles Therapeutics plc

Achilles Therapeutics Plc is a clinical-stage biopharmaceutical company focused on immuno-oncology. The firm specializes in creating innovative precision T-cell therapies designed to combat a range of solid tumors. Its primary therapeutic candidates, both currently undergoing Phase I/IIa clinical trials, are CHIRON, aimed at advanced non-small cell lung cancer, and THETIS, targeting metastatic or recurrent melanoma. Beyond these, Achilles is also advancing its pipeline with treatments for head and neck squamous cell carcinoma, renal cell carcinoma, triple-negative breast cancer, and bladder cancer. Initially incorporated as Achilles TX Limited, the company officially adopted the name Achilles Therapeutics Plc in February 2021. Established in 2016, its corporate headquarters are situated in London, United Kingdom.

CEO: Iraj Ali
IPO Date: Mar 31, 2021

Market Data

Open: $1.48
High: $1.48
Low: $1.48
Volume: 1.2M
52W High: $1.51
52W Low: $0.63

Valuation

Market Cap: $61M
Enterprise Value: $-66M

Financials

Free Cash Flow: $-50M
Revenue: $0
Net Income: $-70M
Cash: $132M
Debt: $4.6M

Events

EarningsNov 12